Trial Outcomes & Findings for The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3) (NCT NCT03583099)

NCT ID: NCT03583099

Last Updated: 2024-09-19

Results Overview

Proportion of CAPTURE+ participants who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation. CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as \<350 L/min for males and \<250 L/min for females. CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

• Recruitment status: COMPLETED
• Study phase: NA
• Target enrollment: 2004 participants
• Primary outcome timeframe: Baseline to 12 months
• Results posted on: 2024-09-19

Participant Flow

Unit of analysis: Practices

Participant milestones

Measure	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.	Enhanced Usual Care: COPD Education Practice clinicians received COPD education only.
Overall Study STARTED	1118 51	886 48
Overall Study Primary Analysis Population	226 49	161 44
Overall Study COMPLETED	802 51	613 46
Overall Study NOT COMPLETED	316 0	273 2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Missing data from 16 participants in the Enhanced Usual Care Arm: COPD Education. Missing data from 31 participants in the Intervention Arm: COPD education plus CAPTURE education and patient-level CAPTURE screening results.

Baseline characteristics by cohort

Measure	Intervention Arm: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=51 practices Intervention Arm: Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.	Enhanced Usual Care Arm: COPD Education n=48 practices Enhanced Usual Care Arm: Practice clinicians received basic COPD education only.	Total n=99 practices Total of all reporting groups
Age, Continuous	62 Years STANDARD_DEVIATION 9 • n=1118 Participants	63 Years STANDARD_DEVIATION 9 • n=886 Participants	62 Years STANDARD_DEVIATION 9 • n=2004 Participants
Sex: Female, Male Female	677 Participants n=1118 Participants	530 Participants n=886 Participants	1207 Participants n=2004 Participants
Sex: Female, Male Male	441 Participants n=1118 Participants	356 Participants n=886 Participants	797 Participants n=2004 Participants
Race/Ethnicity, Customized Non-Hispanic/Non-Latino	984 Participants n=1118 Participants	711 Participants n=886 Participants	1695 Participants n=2004 Participants
Race/Ethnicity, Customized Hispanic or Latino	89 Participants n=1118 Participants	149 Participants n=886 Participants	238 Participants n=2004 Participants
Race/Ethnicity, Customized Don't Know/Prefer not to answer	45 Participants n=1118 Participants	22 Participants n=886 Participants	67 Participants n=2004 Participants
Race/Ethnicity, Customized Missing Data	0 Participants n=1118 Participants	2 Participants n=886 Participants	2 Participants n=2004 Participants
Race/Ethnicity, Customized Black or African American	362 Participants n=1118 Participants	236 Participants n=886 Participants	598 Participants n=2004 Participants
Race/Ethnicity, Customized White	642 Participants n=1118 Participants	514 Participants n=886 Participants	1156 Participants n=2004 Participants
Race/Ethnicity, Customized Other than White or Black/African American	62 Participants n=1118 Participants	44 Participants n=886 Participants	106 Participants n=2004 Participants
Race/Ethnicity, Customized Don't know/Prefer not to answer	52 Participants n=1118 Participants	90 Participants n=886 Participants	142 Participants n=2004 Participants
Body Max Index (BMI)	33 kg/m2 STANDARD_DEVIATION 8 • n=1118 Participants	33 kg/m2 STANDARD_DEVIATION 8 • n=886 Participants	33 kg/m2 STANDARD_DEVIATION 8 • n=2004 Participants
Enrollment Date Before March 20, 2019	284 Participants n=1118 Participants	80 Participants n=886 Participants	364 Participants n=2004 Participants
Enrollment Date March 20, 2019 - November 19, 2019	277 Participants n=1118 Participants	301 Participants n=886 Participants	578 Participants n=2004 Participants
Enrollment Date Sep 20, 2019 - Mar 19, 2020	264 Participants n=1118 Participants	307 Participants n=886 Participants	571 Participants n=2004 Participants
Enrollment Date Mar 20, 2020 or later	293 Participants n=1118 Participants	198 Participants n=886 Participants	491 Participants n=2004 Participants
Education Less than high school	128 Participants n=1118 Participants	118 Participants n=886 Participants	246 Participants n=2004 Participants
Education High school or GED	298 Participants n=1118 Participants	231 Participants n=886 Participants	529 Participants n=2004 Participants
Education Vocational school or some college	310 Participants n=1118 Participants	197 Participants n=886 Participants	507 Participants n=2004 Participants
Education College degree	250 Participants n=1118 Participants	218 Participants n=886 Participants	468 Participants n=2004 Participants
Education Professional or graduate degree	127 Participants n=1118 Participants	118 Participants n=886 Participants	245 Participants n=2004 Participants
Education Missing Data	5 Participants n=1118 Participants	4 Participants n=886 Participants	9 Participants n=2004 Participants
Employment Working part-time or full-time	198 Participants n=1118 Participants	141 Participants n=886 Participants	339 Participants n=2004 Participants
Employment Not working for reason other than disability	488 Participants n=1118 Participants	368 Participants n=886 Participants	856 Participants n=2004 Participants
Employment Not working due to disability	427 Participants n=1118 Participants	376 Participants n=886 Participants	803 Participants n=2004 Participants
Employment Missing	5 Participants n=1118 Participants	1 Participants n=886 Participants	6 Participants n=2004 Participants
Health insurance Private or both private and public insurance	562 Participants n=1118 Participants	467 Participants n=886 Participants	1029 Participants n=2004 Participants
Health insurance Public insurance or no insurance	532 Participants n=1118 Participants	407 Participants n=886 Participants	939 Participants n=2004 Participants
Health insurance Other/Don't know	24 Participants n=1118 Participants	12 Participants n=886 Participants	36 Participants n=2004 Participants
Participants with a history of asthma True	913 Participants n=1118 Participants	723 Participants n=886 Participants	1636 Participants n=2004 Participants
Participants with a history of asthma False	203 Participants n=1118 Participants	162 Participants n=886 Participants	365 Participants n=2004 Participants
Participants with a history of asthma Missing	2 Participants n=1118 Participants	1 Participants n=886 Participants	3 Participants n=2004 Participants
Asthma and respiratory medication No asthma, and no respiratory medication	825 Participants n=1118 Participants	661 Participants n=886 Participants	1486 Participants n=2004 Participants
Asthma and respiratory medication No asthma, but short-acting bronchodilator (SABD) or maintenance respiratory medication	87 Participants n=1118 Participants	62 Participants n=886 Participants	149 Participants n=2004 Participants
Asthma and respiratory medication No asthma with no respiratory medication	67 Participants n=1118 Participants	45 Participants n=886 Participants	112 Participants n=2004 Participants
Asthma and respiratory medication Asthma with SABD only	59 Participants n=1118 Participants	54 Participants n=886 Participants	113 Participants n=2004 Participants
Asthma and respiratory medication Asthma with maintenance respiratory medication	77 Participants n=1118 Participants	62 Participants n=886 Participants	139 Participants n=2004 Participants
Asthma and respiratory medication Missing Data	3 Participants n=1118 Participants	2 Participants n=886 Participants	5 Participants n=2004 Participants
Cigarette smoking Never	518 Participants n=1118 Participants	456 Participants n=886 Participants	974 Participants n=2004 Participants
Cigarette smoking Former	373 Participants n=1118 Participants	283 Participants n=886 Participants	656 Participants n=2004 Participants
Cigarette smoking Current	223 Participants n=1118 Participants	146 Participants n=886 Participants	369 Participants n=2004 Participants
Cigarette smoking Missing	4 Participants n=1118 Participants	1 Participants n=886 Participants	5 Participants n=2004 Participants
Maintenance respiratory medication None	1014 Participants n=1118 Participants	798 Participants n=886 Participants	1812 Participants n=2004 Participants
Maintenance respiratory medication Inhaled Corticosteroids (ICS) alone	31 Participants n=1118 Participants	22 Participants n=886 Participants	53 Participants n=2004 Participants
Maintenance respiratory medication Long-acting brochodilator (LABA) and ICS	63 Participants n=1118 Participants	55 Participants n=886 Participants	118 Participants n=2004 Participants
Maintenance respiratory medication Other combination of LABA, Long-acting beta2-agonist (LAMA), and ICS	9 Participants n=1118 Participants	10 Participants n=886 Participants	19 Participants n=2004 Participants
Maintenance respiratory medication Missing Data	1 Participants n=1118 Participants	1 Participants n=886 Participants	2 Participants n=2004 Participants
Short-acting bronchodilator Use True	197 Participants n=1118 Participants	154 Participants n=886 Participants	351 Participants n=2004 Participants
Short-acting bronchodilator Use False	920 Participants n=1118 Participants	731 Participants n=886 Participants	1651 Participants n=2004 Participants
Short-acting bronchodilator Use Missing Data	1 Participants n=1118 Participants	1 Participants n=886 Participants	2 Participants n=2004 Participants
Number of participants with a COPD Assessment Test (CAT) Score ≥ 10 CAT score < 10	517 Participants n=1118 Participants	451 Participants n=886 Participants	968 Participants n=2004 Participants
Number of participants with a COPD Assessment Test (CAT) Score ≥ 10 CAT score ≥ 10	600 Participants n=1118 Participants	435 Participants n=886 Participants	1035 Participants n=2004 Participants
Number of participants with a COPD Assessment Test (CAT) Score ≥ 10 Missing Data	1 Participants n=1118 Participants	0 Participants n=886 Participants	1 Participants n=2004 Participants
Number of participants with Modified Medical Research Council dyspnea score ≥ 2 True	831 Participants n=1118 Participants	682 Participants n=886 Participants	1513 Participants n=2004 Participants
Number of participants with Modified Medical Research Council dyspnea score ≥ 2 False	285 Participants n=1118 Participants	202 Participants n=886 Participants	487 Participants n=2004 Participants
Number of participants with Modified Medical Research Council dyspnea score ≥ 2 Missing	2 Participants n=1118 Participants	2 Participants n=886 Participants	4 Participants n=2004 Participants
Acute respiratory illness in the past 12 months before baseline True	151 Participants n=1118 Participants	121 Participants n=886 Participants	272 Participants n=2004 Participants
Acute respiratory illness in the past 12 months before baseline False	966 Participants n=1118 Participants	763 Participants n=886 Participants	1729 Participants n=2004 Participants
Acute respiratory illness in the past 12 months before baseline Missing	1 Participants n=1118 Participants	2 Participants n=886 Participants	3 Participants n=2004 Participants
Forced Vital Capacity (FVC) percent of predicted value	82 percent predicted STANDARD_DEVIATION 16 • n=1087 Participants • Missing data from 16 participants in the Enhanced Usual Care Arm: COPD Education. Missing data from 31 participants in the Intervention Arm: COPD education plus CAPTURE education and patient-level CAPTURE screening results.	84 percent predicted STANDARD_DEVIATION 18 • n=870 Participants • Missing data from 16 participants in the Enhanced Usual Care Arm: COPD Education. Missing data from 31 participants in the Intervention Arm: COPD education plus CAPTURE education and patient-level CAPTURE screening results.	83 percent predicted STANDARD_DEVIATION 17 • n=1957 Participants • Missing data from 16 participants in the Enhanced Usual Care Arm: COPD Education. Missing data from 31 participants in the Intervention Arm: COPD education plus CAPTURE education and patient-level CAPTURE screening results.
Forced Expiratory Volume in 1 second (FEV1), percent of predicted value	81 percent predicted STANDARD_DEVIATION 16 • n=1087 Participants • Missing data from 16 participants in the Enhance Usual Care Arm: COPD education. Missing data from 31 participants in the Intervention Arm: COPD education plus CAPTURE education and patient-level CAPTURE screening results.	82 percent predicted STANDARD_DEVIATION 19 • n=870 Participants • Missing data from 16 participants in the Enhance Usual Care Arm: COPD education. Missing data from 31 participants in the Intervention Arm: COPD education plus CAPTURE education and patient-level CAPTURE screening results.	81 percent predicted STANDARD_DEVIATION 17 • n=1957 Participants • Missing data from 16 participants in the Enhance Usual Care Arm: COPD education. Missing data from 31 participants in the Intervention Arm: COPD education plus CAPTURE education and patient-level CAPTURE screening results.
Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) mean	77 percent STANDARD_DEVIATION 8 • n=1087 Participants • Missing data from 16 participants in the Enhanced Usual Care Arm: COPD Education Missing data from 31 participants in the Intervention Arm: COPD Education plus CAPTURE education and patient-level CAPTURE screening results	76 percent STANDARD_DEVIATION 8 • n=870 Participants • Missing data from 16 participants in the Enhanced Usual Care Arm: COPD Education Missing data from 31 participants in the Intervention Arm: COPD Education plus CAPTURE education and patient-level CAPTURE screening results	76 percent STANDARD_DEVIATION 8 • n=1957 Participants • Missing data from 16 participants in the Enhanced Usual Care Arm: COPD Education Missing data from 31 participants in the Intervention Arm: COPD Education plus CAPTURE education and patient-level CAPTURE screening results
Spirometry classification Normal spirometry	478 Participants n=1118 Participants	382 Participants n=886 Participants	860 Participants n=2004 Participants
Spirometry classification Preserved ratio, impaired spirometry	372 Participants n=1118 Participants	278 Participants n=886 Participants	650 Participants n=2004 Participants
Spirometry classification Spirometry-defined COPD	180 Participants n=1118 Participants	164 Participants n=886 Participants	344 Participants n=2004 Participants
Spirometry classification Undetermined	88 Participants n=1118 Participants	62 Participants n=886 Participants	150 Participants n=2004 Participants
CAPTURE question 5 response None	810 Participants n=1118 Participants	672 Participants n=886 Participants	1482 Participants n=2004 Participants
CAPTURE question 5 response Once	154 Participants n=1118 Participants	109 Participants n=886 Participants	263 Participants n=2004 Participants
CAPTURE question 5 response Two or more	154 Participants n=1118 Participants	105 Participants n=886 Participants	259 Participants n=2004 Participants
Practice Baseline Characteristic: Practice Type Part of large health system, Accountable Care Organization (ACO), or similar	17 practices n=51 practices	18 practices n=48 practices	35 practices n=99 practices
Practice Baseline Characteristic: Practice Type Part of academic medical center/health system	15 practices n=51 practices	13 practices n=48 practices	28 practices n=99 practices
Practice Baseline Characteristic: Practice Type Federally Qualified Health Center	10 practices n=51 practices	8 practices n=48 practices	18 practices n=99 practices
Practice Baseline Characteristic: Practice Type Independent practice	6 practices n=51 practices	3 practices n=48 practices	9 practices n=99 practices
Practice Baseline Characteristic: Practice Type Other	2 practices n=51 practices	5 practices n=48 practices	7 practices n=99 practices
Practice Baseline Characteristic: Practice Type Missing	1 practices n=51 practices	1 practices n=48 practices	2 practices n=99 practices
Practice Baseline Characteristic: Number of primary care clinicians 0 - 4	17 practices n=51 practices	17 practices n=48 practices	34 practices n=99 practices
Practice Baseline Characteristic: Number of primary care clinicians 5 -0	21 practices n=51 practices	15 practices n=48 practices	36 practices n=99 practices
Practice Baseline Characteristic: Number of primary care clinicians 10 or more	11 practices n=51 practices	14 practices n=48 practices	25 practices n=99 practices
Practice Baseline Characteristic: Number of primary care clinicians Missing	2 practices n=51 practices	2 practices n=48 practices	4 practices n=99 practices
Practice Baseline Characteristic: Practice is a residency site Yes	13 practices n=51 practices	7 practices n=48 practices	20 practices n=99 practices
Practice Baseline Characteristic: Practice is a residency site No	37 practices n=51 practices	40 practices n=48 practices	77 practices n=99 practices
Practice Baseline Characteristic: Practice is a residency site Missing	1 practices n=51 practices	1 practices n=48 practices	2 practices n=99 practices
Practice Baseline Characteristic: Spirometry is performed in-house Yes	28 practices n=51 practices	30 practices n=48 practices	58 practices n=99 practices
Practice Baseline Characteristic: Spirometry is performed in-house No	22 practices n=51 practices	17 practices n=48 practices	39 practices n=99 practices
Practice Baseline Characteristic: Spirometry is performed in-house Missing	1 practices n=51 practices	1 practices n=48 practices	2 practices n=99 practices
Practice Baseline Characteristic: Rural location Yes	10 practices n=51 practices	8 practices n=48 practices	18 practices n=99 practices
Practice Baseline Characteristic: Rural location No	41 practices n=51 practices	40 practices n=48 practices	81 practices n=99 practices

PRIMARY outcome

Timeframe: Baseline to 12 months

Proportion of CAPTURE+ participants who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Who Meet a Composite Endpoint for Diagnosis and Management of COPD	41.9 percent Interval 34.0 to 49.7	45.9 percent Interval 38.3 to 53.6

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Participants who completed the 12-month follow-up survey, which required them to survive, were included in this analysis.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Who Are Referred for or Complete Clinical Spirometry Testing	19.6 percent Interval 13.0 to 26.3	30.0 percent Interval 22.2 to 37.9

SECONDARY outcome

Timeframe: Baseline to 12 months

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

A new diagnosis of COPD is defined as COPD recorded in the participant's chart or reported by the participant via the follow-up survey.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Who Are Newly Diagnosed With COPD	12.4 percent Interval 6.2 to 18.6	13.7 percent Interval 8.6 to 18.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants With Newly Prescribed Respiratory Medication	27.9 percent Interval 21.5 to 34.4	25.2 percent Interval 19.2 to 31.2

SECONDARY outcome

Timeframe: Baseline to 12 months

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Referred to a Specialist for Respiratory Evaluation/Treatment	12.3 percent Interval 7.8 to 16.8	17.4 percent Interval 11.8 to 23.1

SECONDARY outcome

Timeframe: Baseline to 12 months

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Who Are Referred for or Complete Pulmonary Rehabilitation	7.00 percent Interval 2.9 to 11.2	6.40 percent Interval 2.4 to 10.3

SECONDARY outcome

Timeframe: Baseline to 12 months

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Who Have Received a Recommendation for, or Administration of Influenza Vaccination.	90.8 percent Interval 86.4 to 95.2	84.5 percent Interval 79.4 to 89.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline who had complete follow-up data for all elements of the composite endpoints available were analyzed for this measure.

Proportion of CAPTURE+ participants currently smoking at the baseline visit who have any of the components of the Aim 3 primary endpoint: 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

OR

1) clinical counseling or recommendation for smoking cessation, 2) referral to a smoking cessation program, 3) referral to a smoking quit line, 4) newly prescribed medication for smoking cessation.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=25 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=49 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Smoking at the Baseline With Any Components of the Primary Endpoint OR Any of the 4 Events Described in the Description Below.	85.90 percent Interval 73.93 to 97.87	83.37 percent Interval 82.7 to 84.03

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=29 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=53 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Are Referred for or Complete Clinical Spirometry Testing	24.19 percent Interval 8.8 to 39.58	37.52 percent Interval 24.67 to 50.37

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

A new diagnosis of COPD is defined as COPD recorded in the participant's chart or reported by the participant via the follow-up survey.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=29 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=53 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a New Diagnosis of COPD	23.77 percent Interval 8.8 to 38.74	24.62 percent Interval 13.48 to 35.78

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=29 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=53 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Are Newly Prescribed Respiratory Medication	30.22 percent Interval 15.88 to 44.57	37.05 percent Interval 26.73 to 47.37

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=29 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=53 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral to a Specialist for Respiratory Evaluation/Treatment	13.98 percent Interval 0.36 to 27.61	21.58 percent Interval 9.55 to 33.62

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=29 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=53 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral for, or Complete Pulmonary Rehabilitation.	10.16 percent Interval -1.57 to 21.88	12.01 percent Interval 2.62 to 21.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=29 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=53 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive Clinician Counseling or Recommendation for Smoking Cessation	63.96 percent Interval 44.78 to 83.15	71.98 percent Interval 58.59 to 85.36

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline who had follow-up data available for referral information for smoking cessation programs were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=25 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=50 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral to a Smoking Cessation Program	40.70 percent Interval 20.46 to 60.95	30.36 percent Interval 16.69 to 44.03

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline who had follow-up data available for referral information for a smoking quit line were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=25 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=49 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Capture Positive Participants Currently Smoking at Baseline Who Referral to a Smoking Quit Line	59.54 percent Interval 37.88 to 81.19	55.60 percent Interval 39.32 to 71.88

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants currently smoking at baseline who had follow-up data for newly prescribed medication for smoking cessation were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=25 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=49 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Newly Prescribed Medication for Smoking Cessation.	55.90 percent Interval 35.97 to 75.83	55.14 percent Interval 40.73 to 69.55

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: There was missing data from 2 participants in the Enhanced Usual Care arm and missing data from 4 participants in the Intervention arm.

The COPD Assessment Test (CAT) is scored 0-40. Higher score = more severe COPD impact.

CAPTURE+ is defined as a CAPTURE score ≥ 5, or CAPTURE score 2, 3, or 4 with low PEF (<350 L/min for males,<250 L/min for females). Higher values = higher likelihood of COPD.

The mixed model for 12 month CAT change was: 12 month CAT change = intercept (Enhanced Usual Care (EUC) parameter) + slope (difference between Intervention and EUC) + practice random intercept. 12 month change units are CAT score differences; ie. if 12 month CAT change = 1, CAT score increased by 1 point in 12 months.

Intercept term estimates mean EUC 12 month CAT change. The intercept + slope terms estimate mean intervention group 12 month CAT change.

The slope estimates mean 12 month CAT change differences between Intervention versus EUC where difference direction is: Intervention results minus the EUC results; ie. if the slope = 1, the intervention group had 1 point higher 12 month CAT change compared to EUC.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=159 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=222 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants	-0.93 CAT score point scale Interval -2.21 to 0.34	-1.25 CAT score point scale Interval -2.33 to -0.18

SECONDARY outcome

Timeframe: Baseline to 12 months

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Exacerbation is defined as acute respiratory illness requiring antibiotic/steroid during follow-up.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Who Experience Exacerbations.	15.3 percent Interval 9.7 to 20.8	23.9 percent Interval 17.2 to 30.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for clinically significant COPD were analyzed for this measure.

Proportion of participants with clinically significant COPD who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation. (composite endpoint)

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=39 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=40 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Who Meet Any of the Components of the Primary Endpoint.	48.25 percent Interval 31.56 to 64.94	50.05 percent Interval 33.83 to 66.27

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for clinically significant COPD were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=39 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=40 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD With a Referral for or Completion of Clinical Spirometry Testing	23.04 percent Interval 9.91 to 36.17	17.42 percent Interval 5.72 to 29.13

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for clinically significant COPD were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

A new diagnosis of COPD is defined as COPD recorded in the participant's chart or reported by the participant via the follow-up survey.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=39 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=40 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD With a New Diagnosis of COPD	13.58 percent Interval 2.18 to 24.97	24.26 percent Interval 10.39 to 38.12

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for clinically significant COPD were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=39 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=40 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD With a Newly Prescribed Respiratory Medication	38.42 percent Interval 23.34 to 53.5	24.87 percent Interval 11.58 to 38.16

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for clinically significant COPD were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=39 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=40 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD With a Referral to a Specialist for Respiratory Evaluation/Treatment	9.76 percent Interval 0.72 to 18.8	10.14 percent Interval 0.95 to 19.33

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for clinically significant COPD were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=39 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=40 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD With a Referral for or Completion of Pulmonary Rehabilitation.	12.61 percent Interval 6.1 to 19.11	5.63 percent Interval -0.79 to 12.06

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for clinically significant COPD were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=39 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=40 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Who Receive a Recommendation for or Administration of Influenza Vaccination	94.28 percent Interval 85.74 to 102.82	93.22 percent Interval 84.33 to 102.11

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for spirometric COPD were analyzed for this measure.

Proportion of participants with spirometric COPD who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=119 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=126 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Who Meet Any of the Components of the Primary Endpoint.	36.2 percent Interval 26.6 to 45.9	34.5 percent Interval 24.1 to 44.8

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for spirometric COPD were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=119 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=126 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Referred for or Completion of Clinical Spirometry Testing	15.1 percent Interval 9.1 to 21.2	17.4 percent Interval 10.2 to 24.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for spirometric COPD were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

A new diagnosis of COPD is defined as COPD recorded in the participant's chart or reported by the participant via the follow-up survey.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=119 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=126 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD With a New Diagnosis of COPD.	10.1 percent Interval 4.9 to 15.3	15.9 percent Interval 9.4 to 22.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for spirometric COPD were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=119 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=126 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD With Newly Prescribed Respiratory Medication	22.7 percent Interval 16.1 to 29.3	19.8 percent Interval 12.1 to 27.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for spirometric COPD were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=119 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=126 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Referred to a Specialist for Respiratory Evaluation/Treatment	8.1 percent Interval 2.5 to 13.7	7.6 percent Interval 2.3 to 12.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for spirometric COPD were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=119 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=126 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Who Are Referred for or Complete Pulmonary Rehabilitation.	7.8 percent Interval 3.6 to 12.0	4.0 percent Interval 0.7 to 7.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for spirometric COPD were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=119 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=126 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Who Receive a Recommendation for or Administration of Influenza Vaccination.	89.8 percent Interval 83.6 to 95.9	87.6 percent Interval 81.4 to 93.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD were analyzed for this measure.

Proportion of participants with Mild COPD who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=80 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=86 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Who Meet Any of the Components of the Primary Endpoint	28.66 percent Interval 17.13 to 40.2	27.02 percent Interval 16.48 to 37.57

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=80 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=86 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Referred for or Completion of Clinical Spirometry Testing	11.16 percent Interval 4.13 to 18.2	17.25 percent Interval 9.16 to 25.34

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

A new diagnosis of COPD is defined as COPD recorded in the participant's chart or reported by the participant via the follow-up survey.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=80 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=86 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD With a New Diagnosis of COPD	8.45 percent Interval 2.0 to 14.89	11.36 percent Interval 4.38 to 18.34

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=80 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=86 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD With a Newly Prescribed Respiratory Medication	14.92 percent Interval 6.87 to 22.97	17.29 percent Interval 9.13 to 25.45

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=80 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=86 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Referred to a Specialist for Respiratory Evaluation/Treatment	5.53 percent Interval -0.62 to 11.68	5.89 percent Interval 0.03 to 11.74

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=80 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=86 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Referred for or Completion of Pulmonary Rehabilitation.	7.50 percent Interval 1.72 to 13.27	3.49 percent Interval -0.39 to 7.37

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=80 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=86 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Who Received a Recommendation or Administration of Influenza Vaccination.	87.07 percent Interval 78.36 to 95.79	85.04 percent Interval 76.43 to 93.64

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for preserved ratio, impaired spirometry (PRISm) were analyzed for this measure.

Proportion of participants with preserved ratio, impaired spirometry (PRISm) who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=189 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=271 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Who Meet Any of the Components of the Primary Endpoint.	30.4 percent Interval 24.3 to 36.4	30.4 percent Interval 25.2 to 35.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for preserved ratio, impaired spirometry (PRISm) were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=189 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=271 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred for or Completion of Clinical Spirometry Testing.	15.9 percent Interval 10.5 to 21.2	18.5 percent Interval 14.1 to 22.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for preserved ratio, impaired spirometry (PRISm) were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

A new diagnosis of COPD is defined as COPD recorded in the participant's chart or reported by the participant via the follow-up survey.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=189 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=271 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) With New Diagnosis of COPD.	5.8 percent Interval 2.5 to 9.2	7.4 percent Interval 4.3 to 10.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for preserved ratio, impaired spirometry (PRISm) were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=189 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=271 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) With a Newly Prescribed Respiratory Medication	17.5 percent Interval 12.6 to 22.5	17.4 percent Interval 12.9 to 21.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for preserved ratio, impaired spirometry (PRISm) were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=189 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=271 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred to a Specialist for Respiratory Evaluation/Treatment	11.2 percent Interval 7.5 to 14.9	13.4 percent Interval 9.8 to 17.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for preserved ratio, impaired spirometry (PRISm) were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=189 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=271 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred for or Completion of Pulmonary Rehabilitation.	4.6 percent Interval 1.3 to 7.8	4.4 percent Interval 1.9 to 7.0

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for preserved ratio, impaired spirometry (PRISm) were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=189 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=271 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Who Receive a Recommendation for or Administration of Influenza Vaccination.	85.1 percent Interval 78.9 to 91.4	85.2 percent Interval 80.2 to 90.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) were analyzed for this measure.

Proportion of participants with symptomatic non-obstructed (SNO) meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC<0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=127 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=186 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Meet Any of the Components of the Primary Endpoint.	32.6 percent Interval 23.9 to 41.3	28.4 percent Interval 21.6 to 35.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10.

The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=127 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=186 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred for or Completion of Clinical Spirometry Testing.	14.9 percent Interval 8.6 to 21.2	18.8 percent Interval 13.1 to 24.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10.

The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

A new diagnosis of COPD is defined as COPD recorded in the participant's chart or reported by the participant via the follow-up survey.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=127 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=186 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) With a New Diagnosis of COPD	5.7 percent Interval 1.7 to 9.6	4.8 percent Interval 1.5 to 8.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10.

The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=127 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=186 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Newly Prescribed Respiratory Medication	21.0 percent Interval 13.0 to 29.1	12.3 percent Interval 7.1 to 17.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10.

The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=127 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=186 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred to a Specialist for Respiratory Evaluation/Treatment	10.8 percent Interval 5.9 to 15.7	6.0 percent Interval 2.8 to 9.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10.

The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=127 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=186 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred for or Completion of Pulmonary Rehabilitation.	5.0 percent Interval 1.1 to 9.0	5.4 percent Interval 1.6 to 9.3

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10.

The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=127 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=186 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Who Receive a Recommendation or Administration of Influenza Vaccination.	89.1 percent Interval 83.2 to 95.0	80.4 percent Interval 73.9 to 86.8

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Proportion of CAPTURE+ participants enrolled before March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.	36.04 percent Interval 19.64 to 52.44	52.81 percent Interval 41.97 to 63.65

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

Proportion of CAPTURE+ participants enrolled on or after March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.	42.0 percent Interval 33.5 to 50.5	45.7 percent Interval 36.9 to 54.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Referred for or Complete Clinical Spirometry Testing	18.45 percent Interval -7.2 to 44.1	28.86 percent Interval 13.7 to 44.02

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Referred for or Complete Clinical Spirometry Testing	19.6 percent Interval 12.8 to 26.3	30.4 percent Interval 21.2 to 39.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Newly Diagnosed With COPD	12.70 percent Interval 3.46 to 21.93	13.11 percent Interval 6.46 to 19.75

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Newly Diagnosed With COPD	12.1 percent Interval 5.4 to 18.7	14.8 percent Interval 8.5 to 21.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 With Newly Prescribed Respiratory Medication	22.79 percent Interval 6.23 to 39.34	24.15 percent Interval 14.09 to 34.21

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 With Newly Prescribed Respiratory Medication	28.4 percent Interval 21.4 to 35.4	26.1 percent Interval 19.2 to 33.0

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	7.30 percent Interval -6.18 to 20.77	19.78 percent Interval 8.65 to 30.91

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	12.7 percent Interval 8.1 to 17.3	16.9 percent Interval 10.5 to 23.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation	6.06 percent Interval -4.6 to 16.72	11.34 percent Interval 3.31 to 19.37

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation	6.8 percent Interval 2.4 to 11.1	5.2 percent Interval 1.0 to 9.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Have Received a Recommendation for, or Administration of Influenza Vaccination	95.39 percent Interval 82.91 to 108.87	88.30 percent Interval 78.14 to 98.46

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Have Received a Recommendation for, or Administration of Influenza Vaccination	89.9 percent Interval 85.2 to 94.5	83.3 percent Interval 77.7 to 89.0

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=29 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=53 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Have Received a Recommendation for, or Administration of Influenza Vaccination	82.70 percent Interval 69.16 to 96.24	71.66 percent Interval 59.76 to 83.57

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

The COPD Assessment Test (CAT) is scored 0-40. Higher score = more severe COPD impact.

CAPTURE+ is defined as a CAPTURE score ≥ 5, or CAPTURE score 2, 3, or 4 with low PEF (<350 L/min for males,<250 L/min for females). Higher values = higher likelihood of COPD.

The mixed model for 12 month CAT change was: 12 month CAT change = intercept (Enhanced Usual Care (EUC) parameter) + slope (difference between Intervention and EUC) + practice random intercept. 12 month change units are CAT score differences; ie. if 12 month CAT change = 1, CAT score increased by 1 point in 12 months.

Intercept term estimates mean EUC 12 month CAT change. The intercept + slope terms estimate mean intervention group 12 month CAT change.

The slope estimates mean 12 month CAT change differences between Intervention versus EUC where difference direction is: Intervention results minus the EUC results; ie. if the slope = 1, the intervention group had 1 point higher 12 month CAT change compared to EUC.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants Enrolled Before March 20, 2019	-1.30 CAT score point scale Interval -6.5 to 3.9	-2.44 CAT score point scale Interval -5.08 to 0.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

The COPD Assessment Test (CAT) is scored 0-40. Higher score = more severe COPD impact.

CAPTURE+ is defined as a CAPTURE score ≥ 5, or CAPTURE score 2, 3, or 4 with low PEF (<350 L/min for males,<250 L/min for females). Higher values = higher likelihood of COPD.

The mixed model for 12 month CAT change was: 12 month CAT change = intercept (Enhanced Usual Care (EUC) parameter) + slope (difference between Intervention and EUC) + practice random intercept. 12 month change units are CAT score differences; ie. if 12 month CAT change = 1, CAT score increased by 1 point in 12 months.

Intercept term estimates mean EUC 12 month CAT change. The intercept + slope terms estimate mean intervention group 12 month CAT change.

The slope estimates mean 12 month CAT change differences between Intervention versus EUC where difference direction is: Intervention results minus the EUC results; ie. if the slope = 1, the intervention group had 1 point higher 12 month CAT change compared to EUC.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants Enrolled on or After March 20, 2019	-0.92 CAT score point scale Interval -2.28 to 0.44	-0.92 CAT score point scale Interval -2.15 to 0.31

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low peak expiratory flow (PEF), defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Exacerbation is defined as acute respiratory illness requiring antibiotic/steroid during follow-up.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Exacerbations.	8.78 percent Interval -2.61 to 20.18	26.62 percent Interval 16.12 to 37.13

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low peak expiratory flow (PEF), defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Experience Exacerbations.	15.9 percent Interval 10.0 to 21.7	23.7 percent Interval 15.8 to 31.6

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed 1 year follow-up prior to the COVID-19 pandemic onset.

Proportion of participants with clinically significant COPD enrolled before March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=1 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=7 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 Who Meet Any of Components of the Primary Endpoints.	0 percent Only one participant was in the Enhanced Usual Care group (insufficient data for confidence limits)	42.8 percent Interval 6.2 to 79.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Proportion of participants with clinically significant COPD enrolled on or after March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=38 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=33 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 Who Meet Any of Components of the Primary Endpoints.	49.69 percent Interval 32.76 to 66.63	51.76 percent Interval 33.74 to 69.77

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed 1 year follow-up prior to the COVID-19 pandemic onset.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=1 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=7 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral for or Completion of Clinical Spirometry Testing	0 percent Only one participant was in the Enhanced Usual Care group (insufficient data for confidence limits)	14.3 percent Interval 0.0 to 40.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=38 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=33 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral for or Completion of Clinical Spirometry Testing	23.66 percent Interval 10.19 to 37.14	18.14 percent Interval 5.02 to 31.26

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=1 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=7 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD	0 percent Only one participant was in the Enhanced Usual Care group (insufficient data for confidence limits)	14.3 percent Interval 0.0 to 40.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=38 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=33 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 a New Diagnosis of COPD	13.96 percent Interval 2.28 to 25.65	26.62 percent Interval 10.75 to 42.49

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=1 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=7 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication	0 percent Only one participant was in the Enhanced Usual Care group (insufficient data for confidence limits)	42.8 percent Interval 6.2 to 79.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=38 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=33 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication	39.33 percent Interval 24.21 to 54.45	21.04 percent Interval 7.4 to 34.68

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=1 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=7 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral to a Specialist for Respiratory Evaluation/Treatment	0 percent Only one participant was in the Enhanced Usual Care group (insufficient data for confidence limits)	14.3 percent Interval 0.0 to 40.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=38 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=33 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral to a Specialist for Respiratory Evaluation/Treatment	9.98 percent Interval 0.75 to 19.21	9.31 percent Interval -0.38 to 19.0

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=1 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=7 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral for or Completion of Pulmonary Rehabilitation	0 percent No participants were referred for or competition of pulmonary rehabilitation program.	0 percent No participants were referred for or competition of pulmonary rehabilitation program.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=38 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=33 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral for or Completion of Pulmonary Rehabilitation	12.02 percent Interval 5.03 to 19.01	6.54 percent Interval -0.94 to 14.03

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Clinically significant COPD = post-bronchodilator FEV1/FVC <0.7, plus: 1) FEV1 < 60% predicted or 2) > 1 exacerbation like event in the last year.

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits (CL) are not based on raw data proportions. Reported units are from 0% to 100%. Ie. 50.0 = 50% met outcome.

EUC proportion = intercept. Intervention proportion = intercept + slope.

Intervention minus EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference)

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for different numbers of subjects in practices and correlation of outcomes between subjects in the same practice.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=1 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=7 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination (Abbreviated as Proportion in the Description)	100 percent 100% (1 out of 1 participants) received recommendations for or administration of influenza vaccine. In this case, the raw number of 100% is reported without corresponding (unavailable) confidence limits.	100 percent 100% (7 out of 7 participants) received recommendations for or administration of influenza vaccine. In this case, the raw number of 100% is reported without corresponding (unavailable) confidence limits.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for clinically significant COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7, plus one of the following: 1) FEV1 < 60% predicted or > 1 exacerbation like event within the past 12 months.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=38 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=33 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Clinically Significant COPD Enrolled After August 13, 2020 Who Receive a Recommendation for or Administration of Influenza Vaccination	94.00 percent Interval 85.24 to 102.77	91.13 percent Interval 79.88 to 102.39

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Proportion of participants with spirometric COPD enrolled before March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=8 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=17 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint	29.18 percent Interval 8.37 to 49.98	16.03 percent Interval 0.59 to 31.46

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Proportion of participants with spirometric COPD enrolled on or after March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=111 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=109 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint	37.2 percent Interval 27.0 to 47.4	37.0 percent Interval 25.7 to 48.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Spirometric COPD: post-bronch FEV1/FVC <0.7. If only pre-bronch spirometry is available and FEV1/FVC < 0.65, subject will be considered to have COPD.

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits (CL) are not based on raw data proportions. Reported units are from 0% to 100%. Ie. 50.0 = 50% met outcome.

EUC proportion = intercept. Intervention proportion = intercept + slope.

Intervention minus EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference)

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for different numbers of subjects in practices and correlation of outcomes between subjects in the same practice.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=8 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=17 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing (Abbreviated as Proportion in the Description)	0 percent 0% (0 out of 8 participants) received referral for or completed of clinical spirometry testing. In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.	NA percent Only 1 of 17 subjects was referred for or completed spirometry testing (insufficient for GEE model convergence). Raw proportions don't sufficiently account for different numbers of spirometric COPD subjects in practices and potential correlation of outcomes between individuals in the same practice and aren't reported. Raw proportions and corresponding GEE based model estimates for these proportions aren't equivalent in cluster randomized trials with different sample sizes in each cluster.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=111 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=109 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing	16.2 percent Interval 10.0 to 22.4	19.3 percent Interval 11.3 to 27.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=8 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=17 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD	13.71 percent Interval -5.55 to 32.96	5.10 percent Interval -4.64 to 14.64

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=111 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=109 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 With a New Diagnosis of COPD	9.9 percent Interval 4.4 to 15.4	17.5 percent Interval 10.4 to 24.6

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=8 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=17 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 With Newly Prescribed Respiratory Medication	14.93 percent Interval 0.12 to 29.73	15.75 percent Interval 0.71 to 30.79

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=111 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=109 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 With Newly Prescribed Respiratory Medication	23.5 percent Interval 16.4 to 30.6	20.1 percent Interval 11.7 to 28.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Spirometric COPD: post-bronch FEV1/FVC <0.7. If only pre-bronch spirometry is available and FEV1/FVC < 0.65, participant will be considered to have COPD.

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits (CL) are not based on raw data proportions. Reported units are from 0% to 100%. Ie. 50.0 = 50% met outcome.

EUC proportion = intercept. Intervention proportion = intercept + slope. Intervention minus EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference)

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for different numbers of subjects in practices and correlation of outcomes between subjects in the same practice.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=8 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=17 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment (Abbreviated as Proportion in the Description)	0 percent 0% (0 out of 8 participants) were referred to a specialist for respiratory evaluation/treatment. In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.	NA percent Only 1 of 17 subjects was referred for or completed spirometry testing (insufficient for GEE model convergence). Raw proportions don't sufficiently account for different numbers of spirometric COPD subjects in practices and potential correlation of outcomes between individuals in the same practice and aren't reported. Raw proportions and corresponding GEE based model estimates for these proportions aren't equivalent in cluster randomized trials with different sample sizes in each cluster.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=111 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=109 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	8.7 percent Interval 2.8 to 14.6	7.6 percent Interval 1.9 to 13.3

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=8 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=17 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation	0 percent No participants were referred for or competition of pulmonary rehabilitation program.	0 percent No participants were referred for or competition of pulmonary rehabilitation program.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=111 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=109 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation	8.4 percent Interval 4.0 to 12.8	4.5 percent Interval 0.8 to 8.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=8 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=17 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination	88.42 percent Interval 67.34 to 109.51	88.25 percent Interval 73.23 to 103.27

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for spirometric COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Spirometric COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC <0.7. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=111 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=109 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination	90.1 percent Interval 83.7 to 96.4	87.5 percent Interval 80.6 to 94.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Respiratory medication = long acting bronchodilator or anti-inflammatory

Mild COPD = post-bronch FEV1/FVC<0.7 plus 1) FEV1 ≥ 60% and 2) No prior COPD exacerbation

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits (CL) aren't based on raw data proportions. Reported units are from 0% to 100%. Ie. 50.0 = 50% met outcome

EUC proportion = intercept. Intervention proportion = intercept + slope Intervention - EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference)

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for different numbers of subjects in practices and correlation of outcome between subjects in same practice

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=7 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=10 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Mild COPD Participants Enrolled Before 3/20/2019 With Any of :1) Clinical Spirometry Referral, 2) New COPD Diagnosis, 3) Newly Prescribed Respiratory Medication, 4) Respiratory Specialist Referral, 5) Referral/Completion of Pulmonary Rehab	NA percent Only 2 out of 7 subjects were referred for or completed spirometry testing (insufficient for GEE model convergence). Raw proportions don't sufficiently account for different numbers of spirometric COPD subjects in practices and potential correlation of outcomes between subjects in the same practice and aren't reported. Raw proportions and corresponding GEE based model estimates for these proportions aren't equivalent in cluster randomized trials with different sample sizes in each cluster.	0 percent 0% (0 out of 10 participants) met the components of the primary endpoint. In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for mild COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Proportion of participants with mild COPD enrolled on or after March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=73 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=76 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint	28.9 percent Interval 18.7 to 39.1	30.8 percent Interval 17.9 to 43.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Mild COPD = post-bronch FEV1/FVC<0.7 plus: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits (CL) are not based on raw data proportions. Reported units are on the scale from 0% to 100%. Ie. 50.0 = 50% met outcome.

EUC proportion = intercept. Intervention proportion = intercept + slope.

Intervention minus EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference).

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for different numbers of subjects in practices and correlation of outcomes between subjects in the same practice.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=7 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=10 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing (Abbreviated as Proportion in the Description)	0 percent 0% of participants in this analysis were referred for or competition of spirometry testing. In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.	0 percent 0% of participants in this analysis were referred for or competition of spirometry testing. In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for mild COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=73 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=76 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing	12.5 percent Interval 6.2 to 18.9	20.1 percent Interval 10.3 to 29.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Mild COPD = post-bronchodilator FEV1/FVC<0.7 plus: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits (CL) are not based on raw data proportions. Reported units are from 0% to 100%. Ie. 50.0 = 50% met outcome

EUC proportion = intercept. Intervention proportion = intercept + slope. Intervention minus EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference)

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for different numbers of subjects in practices and correlation of outcomes between subjects in the same practice.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=7 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=10 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD (Abbreviated as Proportion in the Description)	NA percent Only 1 subject was referred for or completed spirometry testing (insufficient for GEE model convergence). Raw proportions don't sufficiently account for different numbers of spirometric COPD subjects in practices and potential correlation of outcomes between individuals in the same practice and aren't reported. In general, raw proportions and corresponding GEE based model estimates for these proportions aren't equivalent in cluster randomized trials with different sample sizes in each cluster.	0 percent 0% of participants in this analysis received a new diagnosis of COPD In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for mild COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=73 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=76 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 With a New Diagnosis of COPD	7.9 percent Interval 1.9 to 13.9	12.8 percent Interval 4.3 to 21.3

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Mild COPD = post-bronchodilator FEV1/FVC<0.7 plus: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits (CL) are not based on raw data proportions. Reported units are from 0% to 100%. Ie. 50.0 = 50% met outcome

EUC proportion = intercept. Intervention proportion = intercept + slope. Intervention minus EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference)

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for different numbers of subjects in practices and c

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=7 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=10 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication (Abbreviated as Proportion in the Description)	NA percent Only 1 out of 7 subjects was referred for or completed spirometry testing (insufficient for GEE model convergence). Raw proportions don't sufficiently account for different numbers of spirometric COPD subjects in practices and potential correlation of outcomes between individuals in the same practice and aren't reported. Raw proportions and corresponding GEE based model estimates for these proportions aren't equivalent in cluster randomized trials with different sample sizes in each cluster.	0 percent 0% (0 out of 10 participants) received referral for or completed of clinical spirometry testing. In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for mild COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=73 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=76 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication	15.0 percent Interval 8.2 to 21.9	19.6 percent Interval 9.2 to 30.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=7 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=10 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	0 percent No participants were referred to a respiratory specialist (insufficient for model convergence).	0 percent No participants were referred to a respiratory specialist (insufficient for model convergence).

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for mild COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=73 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=76 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	6.1 percent Interval 0.6 to 11.5	6.7 percent Interval 0.3 to 13.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for mild COPD enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=7 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=10 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation	0 percent No participants were referred for or competition of pulmonary rehabilitation program (insufficient for model convergence).	0 percent No participants were referred for or competition of pulmonary rehabilitation program (insufficient for model convergence).

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for mild COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=73 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=76 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation	8.2 percent Interval 1.8 to 14.7	4.0 percent Interval -0.2 to 8.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=7 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=10 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Who Received a Recommendation or Administration of Influenza Vaccination	82.7 percent Interval 50.04 to 115.35	77.75 percent Interval 49.8 to 105.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants that met the criteria for mild COPD enrolled on or after March 20, 2019 were analyzed for this measure.

Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC<0.7 plus both of the following: 1) FEV1 ≥ 60% and 2) No prior history of exacerbation of COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=73 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=76 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Who Received a Recommendation or Administration of Influenza Vaccination	87.4 percent Interval 77.2 to 97.7	86.3 percent Interval 77.7 to 94.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISM enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Proportion of participants with preserved ration, impaired spirometry (PRISm) enrolled before March 18, 2020 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=9 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=45 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ration, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.	66.7 percent Interval 35.3 to 98.0	29.03 percent Interval 15.4 to 42.6

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISm enrolled on or after March 20, 2019 were analyzed for this measure.

Proportion of participants with preserved ration, impaired spirometry (PRISm) enrolled on or after March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=180 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ration, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.	28.8 percent Interval 23.1 to 34.6	31.2 percent Interval 25.7 to 36.6

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISM enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=9 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=45 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing	41.27 percent Interval 16.95 to 65.6	18.21 percent Interval 17.49 to 18.93

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISm enrolled on or after March 20, 2019 were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=180 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing	14.4 percent Interval 9.3 to 19.6	17.6 percent Interval 12.6 to 22.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISM enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=9 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=45 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 With New Diagnosis of COPD	9.05 percent Interval -6.59 to 24.68	7.33 percent Interval 1.99 to 12.67

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISm enrolled on or after March 20, 2019 were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=180 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 With New Diagnosis of COPD	5.5 percent Interval 2.2 to 8.8	7.5 percent Interval 4.0 to 11.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISM enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=9 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=45 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication	55.27 percent Interval 24.42 to 86.12	13.17 percent Interval 4.04 to 22.31

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISm enrolled on or after March 20, 2019 were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=180 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication	15.8 percent Interval 11.4 to 20.3	18.3 percent Interval 13.3 to 23.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISM enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=9 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=45 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	29.87 percent Interval 5.46 to 54.27	17.60 percent Interval 10.39 to 24.81

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISm enrolled on or after March 20, 2019 were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=180 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	10.2 percent Interval 6.6 to 13.7	12.6 percent Interval 8.4 to 16.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISM enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=9 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=45 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation	0 percent No participants were referred for competition of pulmonary rehabilitation program (insufficient for model convergence) in the Enhanced Usual Care Arm.	NA percent Only 4 participants were referred for competition of pulmonary rehabilitation program (insufficient for model convergence) in the Intervention Arm.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISm enrolled on or after March 20, 2019 were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=180 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation	4.7 percent Interval 1.4 to 8.0	3.5 percent Interval 0.8 to 6.3

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISM enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Preserved ratio, impaired spirometry (PRISm) = participants without spirometrically defined COPD who have post-bronch FEV1 < 80% predicted.

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits are not based on raw data proportions. Reported units are on the scale from 0% to 100%. Ie. 50.0 = 50% met outcome.

EUC proportion = intercept. Intervention proportion = intercept + slope.

Intervention minus EUC proportion = slope. Ie. 10.0 = Intervention met outcome 10% more than EUC (absolute difference).

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for the different numbers of subjects in practices and correlation of outcomes in the same practice.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=9 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=45 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination (Abbreviated as Proportion in the Description)	100 percent 100% (9 out of 9 participants) received recommendations for or administration of influenza vaccine. In this case, the raw number of 100% is reported without corresponding (unavailable) confidence limits.	NA percent Only 5 of 45 subjects didn't receive a recommendation for the vaccine (insufficient for GEE model convergence). Raw proportions don't sufficiently account for different numbers of vaccine administration in practices and potential correlation of outcomes between individuals in the same practice and aren't reported. Raw proportions and corresponding GEE based model estimates for these proportions aren't equivalent in cluster randomized trials with different sample sizes in each cluster.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for PRISm enrolled on or after March 20, 2019 were analyzed for this measure.

Preserved ratio, impaired spirometry (PRISm) is defined as participants without spirometrically defined COPD who have post-bronchodilator FEV1 < 80% predicted.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=180 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination	84.3 percent Interval 77.8 to 90.9	84.7 percent Interval 79.2 to 90.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Proportion of participants with symptomatic non-obstructed (SNO) enrolled before March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=74 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.	35.2 percent Interval 33.2 to 37.1	35.8 percent Interval 23.1 to 48.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled on or after March 20, 2019 were analyzed for this measure.

Proportion of participants with symptomatic non-obstructed (SNO) enrolled on or after March 20, 2019 who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=107 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=112 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.	33.7 percent Interval 23.5 to 43.9	25.5 percent Interval 16.2 to 34.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=74 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing	25.1 percent Interval 21.7 to 28.5	21.7 percent Interval 13.1 to 30.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled on or after March 20, 2019 were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=107 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=112 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing	13.1 percent Interval 6.1 to 20.2	17.1 percent Interval 9.6 to 24.5

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

SNO = post-bronch FEV1/FVC ≥ 0.7 and post-bronch FEV1 ≥ 80% predicted and a COPD Assessment Test (CAT) score ≥ 10. The CAT is scored 0-40. Higher score = more severe COPD

The generalized estimating equation (GEE) model for the Proportion:

Proportion = intercept (Enhanced Usual Care (EUC) parameter) + slope (Intervention vs. EUC difference). Exchangeable correlation within practice assumed. GEE proportion estimates and confidence limits not based on raw data proportions. Reported units are on the scale from 0% - 100%. Ie. 50 = 50% met outcome

EUC proportion = intercept. Intervention proportion = intercept + slope

Intervention - EUC proportion = slope. Ie 10 = Intervention met outcome 10% > EUC (absolute difference)

When the GEE model does not converge, raw numbers other than 0% or 100% are inappropriate to report, CL are unavailable. Raw proportions do not account for the different numbers of subjects in practices and correlation of outcomes in the same practice

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=74 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 With a New Diagnosis of COPD (Abbreviated as Proportion in the Description)	0 percent 0% (0 of 20 participants) received a new diagnosis of COPD. In this case, the raw number of 0% is reported without corresponding (unavailable) confidence limits.	NA percent Only 4 of 74 participants received a new diagnosis of COPD (insufficient for GEE model convergence). Raw proportions don't sufficiently account for different numbers of new COPD diagnoses in practices, and potential correlation of outcomes between individuals in the same practice and aren't reported. Raw proportions and corresponding GEE based model estimates for these proportions aren't equivalent in cluster randomized trials with different sample sizes in each cluster.

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled on or after March 20, 2019 were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=107 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=112 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 With a New Diagnosis of COPD	6.7 percent Interval 2.2 to 11.1	4.4 percent Interval 0.2 to 8.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=74 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Newly Prescribed Respiratory Medication	15.2 percent Interval -3.5 to 33.8	14.8 percent Interval 7.8 to 21.7

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) enrolled on or after March 20, 2019 were analyzed for this measure.

Respiratory medication = long acting bronchodilator or anti-inflammatory for respiratory condition.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=107 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=112 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Newly Prescribed Respiratory Medication	22.7 percent Interval 13.6 to 31.8	10.6 percent Interval 3.7 to 17.6

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=74 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	9.9 percent Interval 8.5 to 11.2	8.1 percent Interval 4.3 to 11.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for symptomatic non-obstructed (SNO) enrolled on or after March 20, 2019 were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=107 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=112 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment	11.7 percent Interval 5.5 to 18.0	4.5 percent Interval 0.1 to 8.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=74 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation	5.0 percent Interval -1.2 to 11.3	4.1 percent Interval -0.7 to 8.9

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled on or after March 20, 2019 were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=107 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=112 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation	5.6 percent Interval 0.7 to 10.4	6.2 percent Interval 0.8 to 11.6

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled before March 20, 2019 were analyzed for this measure. Participants enrolled before March 20, 2019 completed their 1 year follow-up prior to the COVID-19 pandemic onset.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=74 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Who Receive a Recommendation or Administration of Influenza Vaccination.	94.8 percent Interval 88.6 to 101.0	87.4 percent Interval 79.6 to 95.1

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only participants who met the criteria for SNO enrolled on or after March 20, 2019 were analyzed for this measure.

Symptomatic non-obstructed (SNO) is defined as participants without spirometrically defined COPD (post-bronchodilator FEV1/FVC < 0.7) and without PRISm (post-bronchodilator FEV1 ≥ 80% predicted) who have a COPD Assessment Test score ≥ 10. The COPD Assessment Test (CAT) is an 8-item questionnaire that measures the impact of COPD on a person's life. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=107 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=112 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Who Receive a Recommendation or Administration of Influenza Vaccination.	88.2 percent Interval 81.7 to 94.8	77.0 percent Interval 68.6 to 85.4

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only Capture positive participants currently smoking at baseline who had follow-up data available for over-the-counter patches/gum cessation programs were analyzed for this measure.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=25 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=49 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Received Over-the-counter Patches/Gum for Smoking Cessation	56.18 percent Interval 37.39 to 74.98	41.52 percent Interval 28.48 to 54.57

SECONDARY outcome

Timeframe: Baseline to 12 months

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=161 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=226 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Who Experience Hospitalizations Hospitalized for respiratory illness during follow-up	2 Participants	4 Participants
Proportion of CAPTURE+ Participants Who Experience Hospitalizations No hospitalized for respiratory illness during follow-up	158 Participants	221 Participants
Proportion of CAPTURE+ Participants Who Experience Hospitalizations Missing	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Analysis population is CAPTURE positive participants selected for follow-up. This analysis population does not require a follow-up survey to be completed, hence the size of this analysis population differs from analyses requiring a follow-up survey.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=225 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=331 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Number of Enrolled CAPTURE+ Participants Who Experience Mortality	2 Participants	2 Participants

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=13 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=46 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Hospitalizations	0.0 percent No patients were hospitalized for respiratory illnesses (insufficient variability for confidence limits).	0.0 percent No patients were hospitalized for respiratory illnesses (insufficient variability for confidence limits).

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Only CAPTURE+ participants enrolled on or after March 20, 2019 were analyzed for this measure.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=148 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=180 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Experience Hospitalizations	1.5 percent Interval -0.3 to 3.4	2.1 percent Interval 0.1 to 4.2

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Analysis population is CAPTURE positive participants selected for follow-up and enrolled prior to March 20, 2019. This analysis population does not require a follow-up survey to be completed, hence the size of this analysis population differs from analyses requiring a follow-up survey.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=20 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=72 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Number of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Mortality.	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline to 12 months

Population: Analysis population is CAPTURE positive participants selected for follow-up and enrolled after March 20, 2019. This analysis population does not require a follow-up survey to be completed, hence the size of this analysis population differs from analyses requiring a follow-up survey.

CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as <350 L/min for males and <250 L/min for females.

CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

Outcome measures

Measure	Enhanced Usual Care Arm: COPD Education n=205 Participants Practice clinicians received basic COPD education only.	Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results n=259 Participants Practice clinicians received basic COPD education, CAPTURE education, and clinician receipt of patient-level CAPTURE screening results.
Number of CAPTURE+ Participants Enrolled After March 20, 2019 Who Experience Mortality.	2 Participants	2 Participants

Adverse Events

Intervention: COPD Education Plus CAPTURE Education and Patient-level CAPTURE Screening Results

Serious events: 0 serious events

Other events: 0 other events

Deaths: 2 deaths

Enhanced Usual Care Arm: COPD Education

Serious events: 0 serious events

Other events: 0 other events

Deaths: 2 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Fernando J. Martinez, MD, MS

Weill Cornell Medicine

Phone: 646-962-2370

Email: fjm2003@med.cornell.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place